Exercise of Options, Director/PDMR Dealing & TVR
05/01/2023 07:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230105:nRSE7242La&default-theme=true
RNS Number : 7242L Instem plc 05 January 2023
Instem plc
("Instem" or "the Company")
Exercise of Options, Director/PDMR Dealing and Total Voting Rights
Instem plc (AIM: INS), a leading provider of IT solutions to the global life
sciences market, announces that it was notified on 4 January 2023 that certain
of the Company's Directors and members of its senior management team exercised
share options ("Share Options") over, in aggregate, 61,404 ordinary shares of
10 pence each in the Company ("Ordinary Shares"). The Share Options were
exercised on 4 January 2023 at an exercise price of £0.90 per Ordinary Share.
The Share Options were granted on 14 January 2013 and would have lapsed if
not exercised before 14 January 2023.
Subsequently, also on 4 January 2023, certain Directors sold the Ordinary
Shares issued on the exercise of Share Options in their entirety at a price of
£7.00 per Ordinary Share.
Details of the Directors (each of whom is a person discharging managerial
responsibility or "PDMR") who exercised Share Options and subsequently sold
Ordinary Shares are as follows:
Director No. Share Options exercised No. Ordinary Shares sold Resultant interest in Ordinary Shares Resultant interest in Ordinary Shares as a % of ISC
Phil Reason, CEO 23,429 23,429 770,714 3.39%
Nigel Goldsmith, CFO 15,000 15,000 10,000 0.04%
Issue of Equity and Admission
Application will be made to the London Stock Exchange for the admission of the
61,404 new Ordinary Shares to trading on AIM ("New Ordinary Shares").
Admission is expected to take place at 8.00 a.m. on 10 January 2023.
Total voting rights
Following the issue and allotment of the above New Ordinary Shares, the
Company's issued share capital comprises 22,765,712 Ordinary Shares. The
Company does not hold any Ordinary Shares in treasury. Therefore the total
number of voting rights in the Company is 22,765,712.
The figure of 22,765,712 may be used by shareholders as the denominator for
the calculations by which they will determine if they are required to notify
their interest in, or a change of their interest in, the Company under the
FCA's Disclosure Guidance and Transparency Rules.
For further information, please contact:
Instem plc via Walbrook
Singer Capital Markets (Nominated Adviser & Joint Broker) +44 (0) 20 7496 3000
Peter Steel
Alex Bond
Oliver Platts
+44 (0) 20 7710 7600
Stifel Nicolaus Europe Limited (Joint Broker)
Ben Maddison
Alex Price
Walbrook Financial PR +44 (0) 20 7933 8780
Tom Cooper instem@walbrookpr.com
Nick Rome
About Instem
Instem is a leading provider of IT solutions & services to the life
sciences market delivering compelling solutions for Study Management,
Regulatory Submissions, Clinical Trial Acceleration, and Informatics-based
Insight Generation.
Instem solutions are in use by over 700 customers worldwide, including all of
the largest 25 pharmaceutical companies, enabling clients to bring life
enhancing products to market faster. Instem's portfolio of software solutions
increases client productivity by automating study-related processes while
offering the unique ability to generate new knowledge through the extraction
and harmonisation of actionable scientific information.
Instem products and services address aspects of the entire drug development
value chain, from discovery through to market launch. Management estimate that
over 50% of all drugs on the market have been through some part of Instem's
platform during their development.
To learn more about Instem solutions and its mission, please
visit www.instem.com (http://www.instem.com/)
Notification and public disclosure of transactions by persons discharging
managerial responsibilities ("PDMRs") and persons closely associated with them
The information set out below is provided in accordance with the requirements
of Article 19(3) of the EU Market Abuse Regulation No 596/2014.
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Phil Reason
2 Reason for the notification
a) Position/status CEO
b) Initial notification /Amendment Initial
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Instem plc
b) LEI 213800PILYUFNNROQX68
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary shares of 10p each
Identification code GB00B3TQCK30
b) Nature of the transaction 1. Exercise of Options
2. Sale of Ordinary Shares
c) Price(s) and volume(s)
Price Volume(s)
1. 90p per Ordinary Share (exercise price) 23,429
2. 700p per Ordinary Share (sale price) 23,429
d) Aggregated information n/a - the exercise of options over Ordinary Shares and the sale of Ordinary
Shares each completed as single transactions
- Aggregated volume
- Price
e) Date of the transaction 4 January 2023
f) Place of the transaction In respect of the exercise of options over Ordinary Shares: outside a trading
venue
In respect of the sale of Ordinary Shares: London Stock Exchange, AIM Market
(XLON)
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Nigel Goldsmith
2 Reason for the notification
a) Position/status CFO
b) Initial notification /Amendment Initial
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Instem plc
b) LEI 213800PILYUFNNROQX68
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary shares of 10p each
Identification code GB00B3TQCK30
b) Nature of the transaction 1. Exercise of Options
2. Sale of Ordinary Shares
c) Price(s) and volume(s)
Price Volume(s)
1. 90p per Ordinary Share (exercise price) 15,000
2. 700p per Ordinary share (sale price) 15,000
d) Aggregated information n/a - the exercise of options over Ordinary Shares and the sale of Ordinary
Shares each completed as single transactions
- Aggregated volume
- Price
e) Date of the transaction 4 January 2023
f) Place of the transaction In respect of the exercise of options over Ordinary Shares: outside a trading
venue
In respect of the sale of Ordinary Shares: London Stock Exchange, AIM Market
(XLON)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHUPUPCGUPWGMC